Inclusion Body Myositis (IBM) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) – Pipeline Review, H1 2020’, provides an overview of the Inclusion Body Myositis (IBM) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM)

– The report reviews pipeline therapeutics for Inclusion Body Myositis (IBM) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Inclusion Body Myositis (IBM) therapeutics and enlists all their major and minor projects

– The report assesses Inclusion Body Myositis (IBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Inclusion Body Myositis (IBM)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AAVogen Inc

Abcuro Inc

Alzheon Inc

Cleave Therapeutics Inc

Kv1.3 Therapeutics

Leadiant Biosciences Inc

Milo Biotechnology LLC

Nobelpharma Co Ltd

Orphazyme A/S

PhaseBio Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Inclusion Body Myositis (IBM) - Overview

Inclusion Body Myositis (IBM) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Inclusion Body Myositis (IBM) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development

AAVogen Inc

Abcuro Inc

Alzheon Inc

Cleave Therapeutics Inc

Kv1.3 Therapeutics

Leadiant Biosciences Inc

Milo Biotechnology LLC

Nobelpharma Co Ltd

Orphazyme A/S

PhaseBio Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

Inclusion Body Myositis (IBM) - Drug Profiles

ABC-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aceneuramic acid ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALZ-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arimoclomol citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DEXM-74 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-1023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit VCP/p97 for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UX-001P - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Inclusion Body Myositis (IBM) - Dormant Projects

Inclusion Body Myositis (IBM) - Discontinued Products

Inclusion Body Myositis (IBM) - Product Development Milestones

Featured News & Press Releases

Feb 11, 2020: CytRx highlights recently published data of its licensee Orphazyme A/S Phase 2 trial of Arimoclomol in the treatment of Sporadic Inclusion Body Myositis (sIBM)

Dec 18, 2019: Orphazyme’s arimoclomol receives US fast track designation in sporadic inclusion body myositis

May 02, 2019: CytRx Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme

Apr 29, 2019: CytRx highlights enrollment completion in phase 2/3 clinical trial of Sporadic Inclusion Body Myositis conducted by Arimoclomol Licensee Orphazyme

Apr 23, 2019: Orphazyme's Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled

Apr 25, 2018: New Data Supports Dalazatide from Kv

1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis

Dec 14, 2017: Orphazyme Assumes Sponsorship of Phase II/III sIBM Trial

Nov 07, 2017: Orphazyme Receives Orphan Drug Designation To Arimoclomol For Inclusion Body Myositis From The U.S. FDA

Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union

Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy

Mar 24, 2016: Arimoclomol shows promise in protein misfolding disease

Mar 23, 2016: New drug shows promise against muscle wasting disease

Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency

May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Inclusion Body Myositis (IBM), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by AAVogen Inc, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Abcuro Inc, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Alzheon Inc, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Cleave Therapeutics Inc, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Kv1.3 Therapeutics, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Leadiant Biosciences Inc, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Milo Biotechnology LLC, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Nobelpharma Co Ltd, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Orphazyme A/S, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by PhaseBio Pharmaceuticals Inc, H1 2020

Inclusion Body Myositis (IBM) – Pipeline by Ultragenyx Pharmaceutical Inc, H1 2020

Inclusion Body Myositis (IBM) – Dormant Projects, H1 2020

Inclusion Body Myositis (IBM) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Inclusion Body Myositis (IBM), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports